The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of events cannot be determined.
The post FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products appeared first on MedCity News.
